|
|
|
News:
| July 21, 2010 |
|
BioTime Announces Addition of New Stem Cell Lines to Its Product Portfolio
|
| July 19, 2010 |
|
BioTime, Inc. Provides Financial Information about Its Acquisition of ES Cell International Pte Ltd.
|
| July 9, 2010 |
|
BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2010
|
| July 6, 2010 |
|
BioTime Announces Passing of Board Director Dr. Robert N. Butler
|
| June 18, 2010 |
|
BioTime Commences Warrant Discount Offer
|
| June 14, 2010 |
|
BioTime Announces Results of Vote at Annual Shareholders Meeting
|
| June 13, 2010 |
|
BioTime Set to Join Russell 3000 Index
|
| June 10, 2010 |
|
BioTime Forms New Subsidiary, OrthoCyte Corporation, to Develop Treatments for Orthopedic Conditions Using Stem Cell Technology
Arnold I. Caplan Ph.D., Founder of Osiris Therapeutics, Inc. Appointed Chief Scientific Officer
|
| June 8, 2010 |
|
BioTime CEO Dr. Michael West to Present at the Inaugural Jefferies Global Life Sciences Conference
|
| May 27, 2010 |
|
BioTime Adds Five New Stem Cell Lines to Its Product Portfolio
|
| May 21, 2010 |
|
BioTime CEO Dr. Michael West to Present at GTCbio 6th Annual Stem Cell Research & Therapeutics Conference
|
| May 10, 2010 |
|
BioTime Announces Receipt of $8 Million from Early Exercise of Warrants
|
| May 5, 2010 |
|
BioTime Announces First Quarter 2010 Financial Results and Recent Corporate Developments,159% Increase in Total Revenue for the Quarter
|
| May 3, 2010 |
|
BioTime, Inc. Announces Completion of ES Cell International Pte Ltd Acquisition
|
| April 29, 2010 |
|
BioTime, Inc. Provides Additional Information on Acquisition of Promissory Notes in Connection with Planned Acquisition of ES Cell International Pte Ltd.
|
| April 29, 2010 |
|
BioTime, Inc. Announces Agreement to Acquire ES Cell International
|
| March 16, 2010 |
|
BioTime, Inc. Reports Peer-Reviewed Scientific Publication On The Reversal Of The Developmental Aging Of Normal Human Cells
|
| March 10, 2010 |
|
BioTime Announces Fourth Quarter and Fiscal Year-End 2009 Financial Results and Recent Corporate Developments...163% Increase in Total Revenue for the Quarter...28% Increase in Total 2009 Revenue
|
| February 5, 2010 |
|
BioTime Reports Results from Independent Hextend® Study
|
January 7, 2010
|
|
BioTime Subsidiary OncoCyte Corporation Receives Second $2,000,000 Equity Tranche; BioTime Plans Additional $2,250,000 Investment
|
January 5, 2010
|
|
BioTime Commences Shipment of Stem Cell Research Products to Millipore |
November 24, 2009
|
|
BioTime, Inc. Announces Third Quarter 2009 Financial Results and Update on Recent Developments
|
October 22, 2009
|
|
BioTime, Inc. Announces Approval For NYSE Amex Listing... Trading will begin on Friday
|
October 22, 2009
|
|
Chief Medical Officer of BioTime's Subsidiary OncoCyte Corporation to Deliver Keynote Address at Fifth Chinese Congress on Stem Cell Therapy in Beijing, P.R. China
|
October 15, 2009
|
|
New BioTime Subsidiary, OncoCyte Corporation, Receives $2 Million Equity Financing to Develop Cancer Treatments Using Stem Cell Technology
|
September 24, 2009
|
|
BioTime, Inc. Presentation at 2009 World Stem Cell Summit
|
September 23, 2009
|
|
BioTime, Inc. to Form Asian Subsidiary Enters Into Agreements With Dr. Lu Daopei and Nanshan Memorial Medical Institute Limited
|
September 18, 2009
|
|
BioTime CEO Dr. Michael West to Present Keynote Address at China-USA Scientific Forum of Stem
Cell and Regenerative Medicine
|
September 2, 2009
|
|
BioTime CEO Dr. Michael West to Present at 2009 World Stem Cell Summit |
August 24, 2009
|
|
BioTime, Inc. Completes Exchange Offer for Revolving Line of Credit Notes |
August 10, 2009
|
|
BioTime Appoints Walter Funk Vice President for Stem Cell Research
|
| August 5, 2009 |
|
BioTime, Inc. Commences Exchange Offer for Revolving Line of Credit Notes
|
July 13, 2009
|
|
BioTime Investors Fund Second $4,000,000 Equity Tranche |
July 9, 2009
|
|
BioTime Announces Stem Cell Co-marketing Agreement with Millipore, Millipore to Distribute BioTime's Novel ACTCellerate£ Human Progenitor Cells |
July 7, 2009
|
|
BioTime, Inc. Adds New Members to Its Board of Directors |
May 11, 2009
|
|
BioTime CEO Dr. Michael West to Present at World Stem Cells & Regenerative Medicine Congress 2009, May 14th and Discuss New Cell Lines with Cartilage-Forming Potential |
April 30, 2009
|
|
BioTime Awarded a $4.7 Million Research Grant from the California Institute for Regenerative
Medicine |
March 23, 2009
|
|
BioTime Announces 2008 Year-End Results
|
February 26, 2009
|
|
BioTime's Subsidiary Enters Agreement Adding New Embryonic Stem Cell Lines to Its Product Portfolio
|
January 21, 2009
|
|
BioTime Launches New Stem Cell Lines in Anticipation of President Obama's Removal of Restrictions on Federal Funding of Embryonic Stem Cell Research
|
November 21, 2008
|
|
BioTime INC. Announces Third Quarter 2008 Financial Results--Reports Growth in Third Quarter Revenue-- |
November 19, 2008
|
|
BioTime CEO Dr. Michael West Announces the Launch of New Products and Discusses the State of the Stem Cell Industry under the Obama Administration at the Wisconsin Academy of Sciences, Arts, and Letters |
November 14, 2008
|
|
BioTime CEO Dr. Michael West Presents Keynote Address at Event Commemorating the 10th Anniversary of the First Derivation of Human Embryonic Stem Cells |
October 27, 2008
|
|
BioTime CEO Dr. Michael West Presents at GTCbio Advances in Stem Cell Discoveries Meeting and Announces Launch of New Neural Crest Cell Lines |
October 13, 2008
|
|
BioTime Announces Collaboration with the International Longevity Center on Regenerative Medicine
|
September 18, 2008
|
|
BioTime CEO Dr. Michael West Presents at Tecan Symposium 2008
|
September 11, 2008
|
|
BioTime, Inc. Conference Call Will Discuss Its Recent Acquisition of Stem Cell Technology Licenses
|
Aug 21, 2008
|
|
BioTime, Inc.’ s Subsidiary, Embryome Sciences, Inc., Licenses Virus-Free iPS and Embryonic Stem Cell Differentiation Technology
|
Aug 15, 2008
|
|
BioTime, Inc. Announces Second Quarter 2008 Financial Results |
Aug 6, 2008
|
|
Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
|
July 16, 2008
|
|
Embryome Sciences, Inc. Acquires Exclusive License for ACTCellerate Technology
|
June 27, 2008
|
|
BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative
|
June 25, 2008
|
|
BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
|
May 15, 2008
|
|
BioTime Inc. Announces First Quarter 2008 Financial Results
--Reports Growth in First Quarter Royalty Revenue--
--Expects Continued Growth in Royalty Revenue for Second Quarter-- |
May 6,2008
|
|
BioTime CEO Dr. Michael West Presents at 2008 Seoul Digital Forum Embryonic Stem Cell Research Discussed in Biotechnology Visionaries Panel
|
January 9, 2008
|
|
BioTime Licenses Human Embryonic Stem Cell Technology from the Wisconsin Alumni Research Foundation |
December 18, 2007
|
|
BioTime, Inc. Announces Plan to Map the Human Embryome
|
December 12, 2007
|
|
BioTime, Inc. Announces the Formation of Embryome Sciences, Inc. for the Development and Commercialization of Stem Cell Technology
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|